Nuvation Bio NUVB Interest Receivable On Marketable Securities Current
Interest Receivable On Marketable Securities Current at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept nuvb:InterestReceivableOnMarketableSecuritiesCurrent.
The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's interest receivable on marketable securities current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's interest receivable on marketable securities current?
- Nuvation Bio (NUVB) reported interest receivable on marketable securities current of $3.29M in Q4 2025.
- How has Nuvation Bio's interest receivable on marketable securities current changed year-over-year?
- Nuvation Bio's interest receivable on marketable securities current decreased by 8.0% year-over-year, from $3.57M to $3.29M.
- What is the long-term trend for Nuvation Bio's interest receivable on marketable securities current?
- Over 5 years (2020 to 2025), Nuvation Bio's interest receivable on marketable securities current has grown at a 24.6% compound annual growth rate (CAGR), from $1.09M to $3.29M.
- What does interest receivable on marketable securities current mean?
- This represents the accrued interest income earned on short-term marketable securities that has not yet been received in cash as of the balance sheet date. It reflects the company's ability to generate passive income from its liquid investment portfolio. Monitoring this helps investors assess the yield performance of the company's cash management strategy.